for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

Latest Trade

12.83USD

Change

0.31(+2.44%)

Volume

21,108,539

Today's Range

12.55

 - 

13.94

52 Week Range

2.28

 - 

33.79

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.52
Open
13.45
Volume
21,108,539
3M AVG Volume
346.20
Today's High
13.94
Today's Low
12.55
52 Week High
33.79
52 Week Low
2.28
Shares Out (MIL)
169.41
Market Cap (MIL)
2,027.83
Forward P/E
-10.68
Dividend (Yield %)
--

Next Event

Inovio Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Inovio Announces Initiation Of Phase 2 Segment Of Phase 2/3 Clinical Trial For COVID-19 DNA Vaccine Candidate

Inovio Reports Third Quarter 2020 Financial Results

Inovio Reports FDA Partial Clinical Hold For Planned Phase 2 / 3 Trial Of Covid-19 Vaccine Candidate Ino-4800

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry

Biotechnology & Drugs

Contact Info

6769 Mesa Ridge Rd

SAN DIEGO, CA

92121-2995

United States

+1.858.4103134

http://www.inovio.com/

Executive Leadership

Simon X. Benito

Independent Chairman of the Board

Jong Joseph Kim

President, Chief Executive Officer, Director

Peter D. Kies

Chief Financial Officer

Jacqueline Elizabeth Elizabeth Shea

Chief Operating Officer

Laurent M Humeau

Chief Scientific Officer

Key Stats

2.88 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.080

2018

-1.050

2019

-1.210

2020(E)

-1.174
Price To Earnings (TTM)
--
Price To Sales (TTM)
961.00
Price To Book (MRQ)
6.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
16.58
LT Debt To Equity (MRQ)
16.58
Return on Investment (TTM)
-67.92
Return on Equity (TTM)
-60.62

Latest News

Latest News

Inovio signs COVID-19 vaccine manufacturing deal with Japan's Kaneka

Japan's Kaneka Corp has entered into a deal to manufacture Inovio Pharmaceuticals Inc's COVID-19 vaccine candidate, the U.S.-based vaccine maker said on Thursday.

Inovio to begin mid-stage study of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc has received U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, the vaccine maker said on Monday.

Inovio to begin mid-stage study of COVID-19 vaccine candidate

Inovio Pharmaceuticals Inc said on Monday it had received the U.S. health regulator's clearance to begin a mid-stage study of its COVID-19 vaccine candidate, INO-4800.

Inovio expects FDA decision on COVID-19 vaccine trial start this month

Inovio Pharmaceuticals Inc on Monday said it expects the U.S. Food and Drug Administration to decide this month whether to allow an advanced trial of the company's experimental COVID-19 vaccine to move forward.

Inovio says expects FDA decision on COVID vaccine trial this month

Inovio Pharmaceuticals Inc on Monday said it expects the U.S. Food and Drug Administration to decide this month whether to allow an advanced trial of the company's experimental COVID-19 vaccine to move forward.

FACTBOX-The race for a coronavirus vaccine

More than 150 potential vaccines are being developed and tested globally to stop the COVID-19 pandemic, with 38 in human trials, according to the World Health Organization (WHO). The following list tracks the latest developments from major drugmakers and research institutes...

U.S. FDA pauses Inovio's coronavirus vaccine trial plan

The U.S. health regulator has put a hold on Inovio Pharmaceuticals Inc's plans to start final trials of its coronavirus vaccine as the agency seeks more information, including details on a delivery device used to inject genetic material into cells.

U.S. FDA pauses Inovio's coronavirus vaccine trial plan

The U.S. health regulator has put a hold on Inovio Pharmaceuticals Inc's <INO.O> plans to start final trials of its coronavirus vaccine as the agency seeks more information, including details on a delivery device used to inject genetic material into cells.

Inovio's potential COVID-19 vaccine trial on partial clinical hold

Inovio Pharmaceuticals Inc said on Monday the U.S. Food and Drug Administration had placed a partial clinical hold on the company's planned mid-to-late-stage trial of its experimental coronavirus vaccine candidate.

Inovio partners with Thermo Fisher to bolster COVID-19 vaccine supply

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture the drug developer's experimental coronavirus vaccine, as it looks to boost the supply ahead of large trials this month.

Inovio bolsters COVID-19 vaccine supply with Thermo Fisher deal

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture its experimental coronavirus vaccine to boost the supply of the vaccine.

BRIEF-Inovio Says COVID-19 Vaccine Candidate To Enter Phase 2/3 Study In Sept - Conf Call

* INOVIO PHARMACEUTICALS SAYS COVID-19 VACCINE CANDIDATE TO ENTER PHASE 2/3 STUDY IN SEPTEMBER - CONF CALL

Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in September

Inovio Pharmaceuticals Inc expects its experimental COVID-19 vaccine to enter mid-to-late stage study in September and secure U.S. emergency use authorization sometime in 2021, the U.S. vaccine developer said on Monday.

Inovio vaccine candidate shows promise in non-human study

Inovio Pharmaceuticals Inc said on Thursday its COVID-19 vaccine candidate was effective in protecting rhesus macaques from the virus 13 weeks after the last vaccination.

Inovio vaccine candidate shows promise in non-human study

Inovio Pharmaceuticals Inc said on Thursday its coronavirus vaccine candidate was effective in protecting rhesus macaques from the virus 13 weeks after the last vaccination, sending its shares up 20% before the bell.

Inovio's COVID-19 vaccine candidate shows promise in small early-stage trial

An experimental coronavirus vaccine developed by Inovio Pharmaceuticals Inc <INO.O> showed promise and was found to be safe in an early-stage human trial, the company said on Tuesday.

Inovio's COVID-19 vaccine candidate shows promise in early-stage trial

Inovio Pharmaceuticals Inc on Tuesday reported positive interim data from an early-stage study assessing its potential COVID-19 vaccine wherein patients showed immune response and was deemed safe. (https://reut.rs/2NFcNqL) (Reporting by Trisha Roy in Bengaluru; Editing by...

BRIEF-Inovio Announces Positive Interim Phase 1 Data For Ino-4800 Vaccine For Covid-19

* INOVIO ANNOUNCES POSITIVE INTERIM PHASE 1 DATA FOR INO-4800 VACCINE FOR COVID-19

BRIEF-Inovio Says Established New Unit, Inovio Asia, Through Which Co Intends To Advance Development Projects In South Korea & Other Asian Countries

* INOVIO - ON JUNE 23, ESTABLISHED NEW UNIT, INOVIO ASIA, THROUGH WHICH CO INTENDS TO ADVANCE DEVELOPMENT PROJECTS IN SOUTH KOREA & OTHER ASIAN COUNTRIES Source: https://bit.ly/2VhVKzx Further company coverage:

Inovio gets $71 million from U.S. defense department for COVID-19 vaccine device

Inovio Pharmaceuticals Inc said on Tuesday it has received $71 million from the U.S. Department of Defense (DoD) to scale up production of the company's devices that are used to administer its experimental COVID-19 vaccine into the skin.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up